journal article·2020-06-24

Cationic Liposome/DNA Complexes Mediate Antitumor Immunotherapy by Promoting Immunogenic Tumor Cell Death and Dendritic Cell Activation

Xiuxiu Cong, Huimin Tian, Shuhan Liu, Kuirong Mao, Hongmei Chen, Yanbao Xin, Feiqi Liu, Xin Wang, Xiandi Meng, Ge Zhu, Jialiang Wang, Xue Gao, Huizhu Tan, Yong-Guang Yang, Tianmeng Sun

ACS Applied Materials & Interfaces· Volume 12· Issue 25
Publisher page

Abstract

Immunotherapy has been successfully used in the treatment of multiple malignancies, but clinical studies revealed low response rates. Thus, the development of new effective immunotherapeutic modalities is urgently needed. Successfully inducing tumor cell death with enhanced antigenicity is important for the expansion and differentiation of tumor-specific CD8+ cytotoxic T lymphocytes. Cationic liposome/DNA complexes (CLN/DNA), which usually have obvious cytotoxic effects, may improve the antitumor immunity through enhancing the immunogenicity of dying tumor cells. Herein, we report that a plasmid DNA-encapsulated cationic lipid nanoparticle formulated with cholesterol, DOTAP, and DSPE-mPEG2000 significantly increases the tumor cell death with high antigenicity in vitro. Furthermore, the cationic liposome/DNA complex (CLN/DNA) treatment promotes the activation of dendritic cells (DCs). We also find that the intratumorally injected CLN/DNA successfully promoted the activation of DCs in the tumor-draining lymph node. Importantly, both local tumor growth and distant tumor formation were significantly inhibited by T cell-dependent antitumor immune responses after intratumoral injection of CLN/DNA. This study presents a simple and effective strategy for improving the cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, Jilin 130061, China

National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin 130062, China

International Center of Future Science at Jilin University, Changchun, Jilin 130015, China

State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, Jilin 130012, China

Funding

Ministry of Education of the People's Republic of China · Ministry of Science and Technology of the People's Republic of China · People's Government of Jilin Province · Jilin University · National Natural Science Foundation of China · The First Hospital of Jilin University · Science and Technology Development Program of Jilin Province

References (53)

Show source-provided references
1. 10.1002/stem.171610.1002/stem.1716 ↗
2. 10.1038/nbt.307110.1038/nbt.3071 ↗
3. 10.1038/s12276-018-0191-110.1038/s12276-018-0191-1 ↗
4. 10.7150/jca.2970510.7150/jca.29705 ↗
5. 10.3389/fimmu.2019.0298910.3389/fimmu.2019.02989 ↗
6. 10.1016/j.revmed.2016.05.02310.1016/j.revmed.2016.05.023 ↗
7. 10.1158/0008-5472.CAN-17-310210.1158/0008-5472.CAN-17-3102 ↗
8. 10.1002/JLB.3MIR1017-400R10.1002/JLB.3MIR1017-400R ↗
9. 10.1016/j.jconrel.2017.11.02010.1016/j.jconrel.2017.11.020 ↗
10. 10.1126/science.aad039510.1126/science.aad0395 ↗
11. 10.1016/j.molimm.2018.03.02510.1016/j.molimm.2018.03.025 ↗
12. 10.3389/fimmu.2018.0305910.3389/fimmu.2018.03059 ↗
13. 10.1038/s41467-018-04607-910.1038/s41467-018-04607-9 ↗
14. 10.3390/ijms1902059410.3390/ijms19020594 ↗
15. 10.3389/fimmu.2019.0060410.3389/fimmu.2019.00604 ↗
16. 10.1038/cddis.2016.47310.1038/cddis.2016.473 ↗
17. 10.1111/jcmm.1435610.1111/jcmm.14356 ↗
18. 10.7150/thno.3677710.7150/thno.36777 ↗
19. 10.1016/j.msec.2019.01.06610.1016/j.msec.2019.01.066 ↗
20. 10.1007/s11426-018-9397-510.1007/s11426-018-9397-5 ↗
21. 10.1016/j.biomaterials.2019.11929910.1016/j.biomaterials.2019.119299 ↗
22. 10.1021/acs.biomac.6b0023410.1021/acs.biomac.6b00234 ↗
23. 10.1021/acs.molpharmaceut.5b0094610.1021/acs.molpharmaceut.5b00946 ↗
24. 10.1002/cbin.1045910.1002/cbin.10459 ↗
25. 10.1111/cpr.1219210.1111/cpr.12192 ↗
26. 10.1016/j.cbi.2017.09.00610.1016/j.cbi.2017.09.006 ↗
27. 10.1166/jbn.2017.233710.1166/jbn.2017.2337 ↗
28. 10.1016/j.ijpharm.2017.10.03010.1016/j.ijpharm.2017.10.030 ↗
29. 10.1016/j.biomaterials.2017.11.04010.1016/j.biomaterials.2017.11.040 ↗
30. 10.1038/cr.2015.910.1038/cr.2015.9 ↗
31. 10.7150/thno.2169310.7150/thno.21693 ↗
32. 10.2147/IJN.S7301710.2147/IJN.S73017 ↗
33. 10.1039/C8MO00132D10.1039/C8MO00132D ↗
34. 10.3390/ijms1910289010.3390/ijms19102890 ↗
35. 10.1089/nat.2018.072110.1089/nat.2018.0721 ↗
36. 10.1007/s11426-016-0466-x10.1007/s11426-016-0466-x ↗
37. 10.1016/S1525-0016(03)00233-810.1016/S1525-0016(03)00233-8 ↗
38. 10.1016/j.ejpb.2008.01.03510.1016/j.ejpb.2008.01.035 ↗
39. Yew N. S. · Adv. Gent. · 2005 · 18910.1016/S0065-2660(05)53007-4 ↗
40. 10.1016/j.jinorgbio.2015.04.01610.1016/j.jinorgbio.2015.04.016 ↗
41. 10.1038/ncomms1249910.1038/ncomms12499 ↗
42. 10.4161/21624011.2014.96843410.4161/21624011.2014.968434 ↗
43. 10.4049/jimmunol.178.5.284410.4049/jimmunol.178.5.2844 ↗
44. 10.1038/sj.cgt.770098210.1038/sj.cgt.7700982 ↗
45. 10.1080/0968786060079053710.1080/09687860600790537 ↗
46. 10.1038/sj.cgt.770014310.1038/sj.cgt.7700143 ↗
47. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
48. 10.1006/mthe.2001.046310.1006/mthe.2001.0463 ↗
49. Dow S. W. · J. Immunol. · 1999 · 163 · 155210.4049/jimmunol.163.3.1552 ↗
50. Lanuti M. · Cancer Res. · 2000 · 60 · 2955
51. 10.18632/oncotarget.1862710.18632/oncotarget.18627 ↗
52. 10.1016/j.cell.2016.12.02210.1016/j.cell.2016.12.022 ↗
53. 10.1038/s41591-019-0498-z10.1038/s41591-019-0498-z ↗